2,626 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by Neo Ivy Capital Management

Neo Ivy Capital Management acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,626 shares of the medical research company's stock, valued at approximately $878,000.

Several other institutional investors have also added to or reduced their stakes in the company. Capital Advisors Ltd. LLC raised its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after buying an additional 62 shares in the last quarter. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Gladius Capital Management LP acquired a new position in Bio-Rad Laboratories during the third quarter worth about $32,000. Headlands Technologies LLC bought a new position in shares of Bio-Rad Laboratories in the second quarter worth about $51,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $55,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price objective for the company. Royal Bank of Canada upped their price target on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an "outperform" rating in a report on Monday. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Finally, Citigroup upped their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $394.20.

Bio-Rad Laboratories Trading Down 0.4 %

Shares of NYSE:BIO traded down $1.49 during mid-day trading on Thursday, reaching $340.02. 106,449 shares of the company's stock were exchanged, compared to its average volume of 241,916. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The firm has a market capitalization of $9.52 billion, a price-to-earnings ratio of -12.44 and a beta of 0.90. The business's fifty day moving average price is $341.51 and its 200-day moving average price is $320.45.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business's quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.33 EPS. On average, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.